Prevalence of human T-cell lymphotropic virus type 1 or 2 among blood donors screened at the New Zealand Blood Service: An observational study, 2001–2024

Simple item page
dc.citation.volume58
dc.contributor.authorAye PS
dc.contributor.authorGray L
dc.contributor.authorCharlewood R
dc.contributor.authorBennett W
dc.contributor.authorBromhead C
dc.contributor.authorBalm M
dc.contributor.authorCrengle S
dc.contributor.authorBartholomew K
dc.date.accessioned2025-09-22T00:48:06Z
dc.date.available2025-09-22T00:48:06Z
dc.date.issued2025-10
dc.description.abstractObjective To investigate prevalence of Human T-cell Lymphotropic Virus type 1 or 2 (HTLV-1/2) using the New Zealand Blood Service (NZBS) data, to inform whether further HTLV-1/2 prevalence study may be required, in the context of drivers of the inequities in lung cancer for Māori (the Indigenous population). Methods This observational cross-sectional study used the NZBS data of all blood donors nationwide (01/01/2001–30/06/2024). Prevalence overall and by ethnicity was calculated as the number of confirmed HTLV-1/2 positive cases per 10,000 donors. Results Of 679,946 new donors over the 23.5 years, 25 HTLV-1/2 positive cases were identified. The overall prevalence of HTLV-1/2 in New Zealand was 0.4 cases per 10,000 donors, highest among Middle Eastern, Latin American and African ethnicity (six cases per 10,000 donors), with no positive cases in Māori and Pacific donors. Among the positive cases, the highest proportions were seen separately for those aged 25–34, females, of New Zealand European ethnicity, resident in Auckland, and born in India, compared to their counterparts. Conclusions Prevalence of HTLV-1/2 infection among blood donors in New Zealand was very low, with no evidence of infection among Māori and Pacific donors, suggesting that a wider HTLV-1/2 seroprevalence study was unlikely to be necessary.
dc.description.confidentialfalse
dc.edition.editionOctober 2025
dc.identifier.citationAye PS, Gray L, Charlewood R, Bennett W, Bromhead C, Balm M, Crengle S, Bartholomew K. (2025). Prevalence of human T-cell lymphotropic virus type 1 or 2 among blood donors screened at the New Zealand Blood Service: An observational study, 2001–2024. Preventive Medicine Reports. 58.
dc.identifier.doi10.1016/j.pmedr.2025.103223
dc.identifier.eissn2211-3355
dc.identifier.elements-typejournal-article
dc.identifier.number103223
dc.identifier.piiS2211335525002621
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/73589
dc.languageEnglish
dc.publisherElsevier B.V.
dc.publisher.urihttps://www.sciencedirect.com/science/article/pii/S2211335525002621
dc.relation.isPartOfPreventive Medicine Reports
dc.rights(c) 2025 The Author/s
dc.rightsCC BY-NC 4.0
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectHuman T-cell Lymphotropic virus
dc.subjectHTLV
dc.subjectPrevalence
dc.subjectBlood donor
dc.subjectNew Zealand
dc.titlePrevalence of human T-cell lymphotropic virus type 1 or 2 among blood donors screened at the New Zealand Blood Service: An observational study, 2001–2024
dc.typeJournal article
pubs.elements-id503209
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
503209 PDF.pdf
Size:
419.75 KB
Format:
Adobe Portable Document Format
Description:
Published version.pdf
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles